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Abstract 
BACKGROUND: Mild cognitive impairment (MCI) is a stage between the expected cognitive decline of normal 
ageing and the serious decline of dementia. 
AIM: To identify risk factors and role of miRNAs associated with mild cognitive impairment (MCI) among 
employees. 
SUBJECTS AND METHOD: A cross-sectional study was carried out on 186 employees aged between 40 and 65 
years. Cognitive function was evaluated using ACEIII, MoCA, and Quick cognitive tests. Medical history and 
lifestyle were assessed. Family 132 & 134 miRNA expressions were assessed by real-time PCR. 
RESULTS: MCI was detected among 14 / 186 (7.5%). miRNA 132 expression was the only significant miRNAs to 
detect MCI with low sensitivity and specificity (70%). The logistic analysis revealed that higher miRNA132 
expressions, low monthly intake of; vegetables, unroasted nuts, low education and higher ALT levels were 
predicting factors for MCI with AOR 1.1 (1.01-3.3), 1.2 (1.04-1.43), 0.8 (0.8-0.98), 2.7 (1.9-7.4) and 1.6 (1.1-2.3) 
respectively. 
CONCLUSION: MiRNAs expression showed low sensitivity and specificity in detecting MCI; only miRNA 132 
might be used. Several modifiable factors seem to reduce the risk of MCI. 
 
 
 
 
 
Introduction 
 
Mild cognitive impairment (MCI) is a stage 
between the cognitive decline of normal ageing and 
dementia. MCI involves the onset and evolution of 
problems related to memory, language, and thinking 
beyond those expected for age. People with MCI are 
at greater risk of later developing dementia. However, 
some of them never get worse, and a few get better 
[1]. 
Detecting intervenable risk factors is a key 
component of preventive strategies for mild cognitive 
impairment [2]. Medical and lifestyle factors that have 
been related to an increased risk of cognitive 
impairment include hypertension, diabetes, elevated 
cholesterol, depression, infrequent participation in 
mentally or socially stimulating activities, and smoking 
[3], [4]. 
MicroRNA (miRNA), is a small non-coding 
RNA molecule that functions in the regulation of gene 
expression. It plays an important role in the 
pathogenesis of many diseases. It has been reported 
that miR-132 is linked with cognitive impairment [5].
 
MiRNAs are actively secreted and expressed in body 
fluids, such as plasma and cerebrospinal fluid (CSF) 
[6], [7], [8]. 
This study aimed to assess the potential risk 
factors of MCI among employees at the National 
Research Center (NRC) and the role of family 132 
and 134 miRNAs expression. 
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Subjects and Methods 
 
Study design  
A cross-sectional study was carried out on 
186 adults aged between 40 and 65 years recruited 
from NRC employees. Recruitment of participants and 
data collection was carried out along one year during 
the period between June 2016 and December 2017. 
Employees with diabetes, neurological and psychiatric 
illness, major organ failure and cancer were excluded 
from the study. 
 
Ethical statement 
This work has been carried out by The Code 
of Ethics of the World Medical Association 
(Declaration of Helsinki). Each study participant 
provided informed written consent after 
acknowledgement about the research and the study 
was approved by the Ethical Committee of the 
National Research Centre (registration number 
15131). 
 
 
Methods 
 
Assessment of risk factors for MCI 
A closed-ended questionnaire module was 
designed to cover data on demographic 
characteristics and full medical history. Data included 
age, gender and education. Data on tobacco smoking, 
physical activity, dietary habits were also collected to 
identify risk factors associated with MCI. The 
questionnaire was tested for the clarity & flow of the 
questions, and the time required to complete it. A 
consent form was also signed by all the participants 
before the interview.  
 
Assessment of cognitive function with its 
 domains 
The case definition of MCI was derived from 
the National Institute on Aging–Alzheimer’s 
Association recommendations [9]. It includes the 
following clinical criteria for the diagnosis of MCI. 
 
Subjective Concern as regards the change 
 in cognition 
We measured subjective cognitive concerns 
through two questions, according to Lara et al., [10]. 
“How would you most describe your memory 
at present?”, with answer options being very good, 
good, moderate, bad or very bad, and “Compared to 
12 months ago, would you say your memory is now 
better, the same or worse than it was then?”.  
Participants were evaluated to have memory 
weakness if they answered “bad” or “very bad” to the 
former question and / or “worse” to the latter. 
 
Objective Impairment in one or more 
 cognitive domains 
Changes can occur in a diversity of cognitive 
domains, including memory, executive function, 
attention, language, and visuospatial skills. To assess 
global and specific cognitive domains, we choose the 
most reliable and validated Arabic forms scales or 
easily translated cognitive scales and freely available 
to be applied to the studied subjects. The following 
tests were used to assess MCI: 
 
A) Montreal Cognitive Assessment test 
 (MoCA) 
It comprises five neurological domains: 
executive function, attention, short-term memory, 
language, and visuospatial [11].
 
It is available in 
Arabic version [12]. 
 
B) Addenbrooke's Cognitive Examination 
 III (ACE III) 
It is available in Arabic [13].
 
It assesses MCI 
and early stages of dementia [13], [14]. 
 
C) The Quick Mild Cognitive Impairment 
 (Quick MCI) 
It assesses the five domains of cognitive 
function: registration, orientation, delayed recall, clock 
drawing and verbal fluency (VF) [15], [16].
 
It is easily 
translatable (linguistically and culturally) and has 
alternative forms, which allow follow up of cognitive 
function over time [17]. 
 
The recommended cut-off points for each 
 studied cognitive scale were utilized to 
 detect objective cognitive impairment 
The cut-off point for ACE III score < 88 [18],
 
for MoCA score < 26 [19]
 
and for Quick MCI score < 
67 [20]. 
Objective MCI was considered if two or all of 
the three studied cognitive tests were below the cut-
off points. 
Preservation of independence in daily 
functional abilities, such as paying bills, preparing a 
meal, or shopping. 
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Clinical Assessment 
All studied participants were subjected to 
thorough clinical examination. The anthropometric 
assessment included weight, height, waist and hip 
circumference, and body mass index (BMI) was 
calculated. Blood pressure was measured. 
Laboratory analysis: - Fasting peripheral 
blood samples (10 ml) were withdrawn from each 
participant under complete aseptic conditions and 
after 10 fasting hrs. Part of the blood sample was 
anticoagulated with EDTA for assessment of the 
glycated haemoglobin (HbA1c) using Labona check™ 
HbA1c analyser and measurement of selected 
MicroRNAs by real-time PCR. The other part of the 
blood sample was left to clot and sera were separated 
immediately for analysis of fasting blood sugar, lipid 
profile, liver and kidney functions by Erbaxl -300 
Mannheim Gmbh Germany; and - MicroRNA isolation 
and real-time RT-PCR. 
MicroRNA was isolated according to the 
manufacturer’s instructions using miRNeasy Mini Kit 
(Cat. No. 217004) and QIAzol Lysis Reagent supplied 
by QIAGEN, Germany. Concentration and purity of 
the yield were determined using Nanodrop 2000, 
USA. Synthesis of cDNA was performed via thermal 
cycler (Verity, Applied Biosystems, USA) using the 
TaqMan® Advanced miRNA-cDNA synthesis kit (cat. 
No A28007) supplied by Applied Biosystems, Life 
Technologies, USA. 
The relative quantity of (miRNA-128, miRNA-
132, miRNA-874) and (miRNA-134, miRNA-323, 
miRNA-382) in plasma were measured by qRT-PCR 
via TaqMantechnology using QuantStudio™ 12K Flex 
real-time PCR system (Applied Biosystems, USA). 
MicroRNAs’ levels were determined by the 
comparative CT (ΔΔCT) method via the Expression 
Suite Software using miRNA-491 and miRNA-370 
levels, respectively for normalisation. 
 
Data analysis 
Data entry was carried on excel sheet, and 
statistical analysis was done using Statistical program 
for social science (SPSS) version 18 for windows 
SPSS; Inc, Chicago IL. Continuous data were 
expressed as mean and standard deviation Number 
and percent were used to describe categorical data. 
Chi square test was used for comparing between two 
qualitative variables. T-test was used for comparing 
between two means. Non-parametric tests were used 
in cases of not normally distributed data. The Bivariate 
correlations procedure (Pearson correlation) was used 
to calculate the pairwise associations for a group of 
variables. Receiver-Operating Characteristic (ROC) 
curves were formed and the area under ROC curves 
(AUC) was determined to assess sensitivity and 
specificity of various miRNAs biomarkers. The cutoff 
points on the ROC curves, where the accuracy of MCI 
detection is greatest, were determined. P-value was 
considered statistically significant if p < 0.05 and 
considered statistically highly significant if p < 0.01. 
 
Results 
 
Regarding socio-demographic data, there 
were 73 (36.6%) males and 113 (63.4%) females, 
their ages ranged from 40 to 65 years with a mean of 
51.3 ± 4.1 years. About 41% of the studied individuals 
had secondary education, 42% had a university 
education, and 17% had a post-graduate level of 
education. As regards the subjective complaint of 
memory impairment, about 60% of all participants 
complained of frequent forgetfulness. Comparing their 
current memory to that of the previous year, 31.9% of 
them reported impaired memory. MCI was detected 
among 14 / 186 (7.5%) of the studied individuals 
depending on both subjective complaint and objective 
detection with at least two positive cognitive tests. The 
mean score of ACE III (88.14 ± 2.5), MOCA (25.29 ± 
2.09) and Quick MCI (63.42 ± 9.78) tests was 
significantly lower among individuals with confirmed 
MCI compared to those with normal cognition (94.5 ± 
4.5), (27.9 ± 2.2) and (77.6 ± 10.09) respectively, P < 
0.01. 
The percentage of subjects with MCI was 
significantly higher among current or ex-smokers 
compared to nonsmokers and among individuals with 
sedentary life compared to those with physical 
activities, P < 0.05. Mean BMI was significantly higher 
among individuals with MCI compared to those with 
normal cognition, P < 0.01 (Table 1). 
Table 1: Socio-demographic, medical and physical history of 
the studied participants about MCI 
Variable Total Cognitive function  
Odds Ratio 
(CI 95%) 
MCI 
(N = 14) 
N (%) 
Normal 
(N = 172) 
N (%) 
Age in years 
< 50 
50 -< 55 
55 -< 60 
60-65 
 
65 
64 
42 
15 
 
5 (7.8) 
6 (9.4) 
3 (7.1) 
0 (0.0) 
 
60 (92.2) 
58 (90.6) 
39 (92.9) 
15 (100.0) 
 
® 
1.2(0.3-4.3) 
0.9(0.2-4.1) 
 
Gender 
Males 
Females 
 
73 
113 
6 (8.2) 
8 (7.1) 
67 (91.8) 
105 (92.9) 
1.1 (0.3-3.5) 
® 
Education 
Secondary 
University and Master / MD 
 
79 
107 
 
9 (11.3) 
5 (4.7) 
 
70 (88.7) 
102 (95.3) 
2.6 (0.8-8.2) 
® 
Smoking 
Current or ex-smokers 
Non-smokers 
 
31 
155 
 
5 (16.1) 
9 (5.8) 
 
26 (83.9) 
146 (94.2) 
3.1(0.96-10.1) * 
® 
Marital status 
Married 
Single or widowed 
 
150 
36 
 
14 (9.3) 
1 (2.7) 
 
136 (90.7) 
36 (100.0) 
3.7 (0.5-29.1) 
® 
Family history of dementia 
Yes 
No 
 
45 
141 
 
3 (6.6) 
11 (7.8) 
 
42 (93.4) 
130 (92.2) 
0.8(0.2-3.1) 
® 
History of head Trauma 
Yes 
No 
 
44 
142 
 
3 (6.8) 
11 (7.7) 
 
41 (92.3) 
131 (92.3) 
 
0.8(0.2-3.2) 
® 
Physical activities 
No  
Several times/month 
 
40 
123 
 
6 (15.0) 
5 (4.1) 
 
34 (85.0) 
118 (95.9) 
 
4.2(1.2-14.5)*  
® 
Systolic blood pressure (mean ± 
SD) 
186 120 ± 14.1 118 ± 14.9 P > 0.05 
Diastolic blood pressure (mean 
± SD) 
186 78.5 ± 7.7 77.5 ± 10.7 P > 0.05 
BMI (mean ± SD) 186 35.5 ± 7.2 30.8 ± 5.6 P < 0.01 
Waist/Hip ratio (mean ± SD) 186 0.88 ± 0.08 0.87 ± 0.07 P > 0.05 
® Reference group; CI: confidence interval; * Significant P value < 0.05. 
 
The mean monthly intake of important food for 
good memories like vegetables, dark green 
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vegetables and unroasted nuts were significantly 
higher among those with normal cognition compared 
to those with MCI, P < 0.01. The mean monthly hours 
spent on the internet, playing intellectual games and 
going to the museum / cinema was significantly lower 
among participants with MCI (P < 0.01) (Table 2). 
Table 2: Monthly frequency intake of some food items, social 
and mental activities of the studied participants about MCI 
 Variable 
Cognitive function 
 
 
P-value 
MCI Normal 
N = 14 
(Mean ± SD) 
N = 172 
(Mean ± SD) 
Main Meal contain  
(vegetables- carbohydrates- protein) 
11.3 ± 9.4 21.1 ± 27.9 0.249 
Red meat 5.0 ± 3.0 5.4 ± 4.5 0.748 
Egg 8.5 ± 10.9 12.6 ± 10.0 0.201 
Dairy products 23.5 ± 9.3 25.4 ± 12.3 0.603 
Fish 5.7 ± 8.3 4.6 ± 7.5 0.623 
Canned tuna 0.9 ± 0.8 1.9 ± 4.1 0.446 
Bean 8.0 ± 11.3 15.4 ± 12.3 0.059 
Whole brown Grain 1.3 ± 2.5 4.3 ± 10.2 0.336 
Vegetable 4.2 ± 8.7 19.4 ± 16.1 0.000* 
Dark green vegetables 1.0 ± 1.1 4.9 ± 7.7 0.000* 
Fruits 12.7 ± 9.6 21.1 ± 14.1 0.055 
Unroasted nuts 0.4 ± 0.5 3.6 ± 7.1 0.000* 
Dark chocolate 0.4 ± 0.5 2.8 ± 6.5 0.219 
Social activities 
Going to Club 
 
1.0 ± 1.6 
 
2.4 ± 6.8 
 
0.520 
Going to Museum/ Cinema/ parties  0.0 ± 0.0 0.2 ± 0.5 0.000* 
Mental activities (In hours) 
Watching TV  
 
79.1 ± 70.1 
 
51.3 ± 50.4 
 
0.088 
Using Internet  21.8 ± 14.0 36.9 ± 33.3 0.007* 
Playing intellectual games 0.7 ± 0.3 6.2 ± 14.9 0.000* 
P significant at < 0.05. 
 
None of the studied laboratory tests was 
found to be significantly associated with MCI (P > 
0.05) (Table 3). 
Table 3: Lipid profile and other laboratory analysis of the 
studied participants and MCI 
Laboratory Test 
Cognitive function 
 
 
P-value 
MCI Normal 
N = 14 
Mean ± SD 
N = 172 
Mean ± SD 
Alanine 
aminotransferase (ALT) 
21.4 ±14.1 19.2±10.5 0.467 
Albumin (ALB) 4.5 ± 0.2 4.6 ± 0.2 0.128 
Creatinine 0.9 ± 0.1 0.9 ± 0.1 0.539 
Fasting Blood Glucose 
(FBG) 
117.8 ± 31.2 96.5 ± 31.2 0.134 
Glycosylated 
Hemoglobin (HbA1c) 
6.2 ± 1.5 5.5 ± 1.2 0.620 
Cholesterol  181.7 ± 16.8 189.5 ± 14.2 0.073 
Triglycerides 107.1 ± 81.5 120.7 ± 49.0 0.401 
High Density lipoprotein 
(HDL) 
42.3 ± 14.5 46.3 ± 13.6 0.348 
Low Density lipoprotein 
(LDL) 
122.7 ± 22.1 125.1 ± 20.3 0.092 
P non-significant > 0.05. 
 
ROC curve analysis was done for miRNA 
128, miRNA-132, miRNA-874, miRNA-134, miRNA-
323 and miRNA-382 expressions in plasma of the 
studied subjects. Upon analysis, only miRNA-132 can 
significantly differentiate between MCI and normal 
cognition with AUC = 0.69 with a 95% confidence 
interval 0.52 – 0.86 (P = 0.04) (Figure 1).  
These biomarker pairs for family miRNA 132 
expressions differentiated individuals with MCI from 
those with normal cognition with 60%-70% sensitivity 
and 57.9%-68.6% specificity. 
 
Figure 1: Receiver‐Operating Characteristic (ROC) curve for 
differentiation between MCI and normal cognition among apparently 
healthy individuals obtained with different miRNAs biomarker pairs 
 
Family miRNA 134 expressions differentiated 
individuals with MCI from those with normal cognition 
with 40%-60% sensitivity and 65.2%-83.3% specificity 
(Table 4). 
Table 4: Sensitivity, specificity and ACU of MiRNA biomarker 
pairs in detecting MCI 
Family / normalizer  AUC (95% CI) Sensitivity Specificity Accuracy P-value 
miRNA-128 / miRNA-491 0.56 (0.37-0.74) 60% 68.6% 64.3% 0.5 
miRNA-132 / miRNA-491 0.69 (0.52-0.86) 70% 68.6% 69.3% 0.04 
miRNA-874 / miRNA-491 0.49 (0.34-0.63) 60% 57.9% 58.9% 0.9 
miRNA-134 / miRNA-370 0.52 (0.26-0.78) 40% 83.3% 61.6% 0.8 
miRNA-323 / miRNA-370 0.57 (0.38-0.77) 60% 65.2% 62.6% 0.4 
miRNA-382 / miRNA-370 0.64 (0.44-0.84) 50% 71.9% 60.9% 0.1 
AUC: area under the curve. 
 
Logistic regression analysis revealed higher 
miRNA132 expressions, little vegetables, little nuts, 
lower level of education and a higher level of ALT are 
predicting factors for MCI with AOR 1.1 (1.01-3.3), 1.2 
(1.04-1.43), 0.8 (0.8-0.98), 2.7 (1.9-7.4) and 1.6 (1.1-
2.3) respectively (Table 5). 
Table 5: Logistic regression analysis for predicting the risk of 
MCI  
Variable Adjusted Odds Ratio 
95% confidence interval 
P-value 
Lower Upper 
miRNA132 1.12 1.01 3.387 0.007 
no vegetables 
no nuts 
1.2 
0.88 
1.04 
0.80 
1.43 
0.98 
0.01 
0.02 
secondary education 2.7 1.96 7.4 0.04 
ALT lab 1.586 1.079 2.332 0.019 
Constant 1.459E23   0.017 
 
 
 
Discussion 
 
The risk of dementia is higher in individuals 
with MCI (10-15%) compared to others with normal 
cognition (1-2%) [21], [22], [23]. 
In the present study, the prevalence of MCI 
was 7.5%. In a study done among doctors and 
workers at Zagazig University Hospital, Egypt, with a 
Salama et al. Risk Factors Associated with Mild Cognitive Impairment Among Apparently Healthy People and the Role of MicroRNAs 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Oct 15; 7(19):3253-3261.                                                                                                                                                 3257 
 
similar age group, MCI was found among 9% of them 
[24].
 
In China, in Tianjin city, MCI was detected among 
9.7% of normal individuals according to the Petersen's 
criteria of MCI [25].
 
Ding and Zhao [26]
 
documented 
MCI prevalence of 20.1% among normal Chinese 
individuals aged ≤ 60 years in an urban community of 
Shanghai using Mini-Mental status test. Moreover, 
Salama et al., [27]
 
found that the prevalence of MCI 
was 11.6% among non-obese aged 40-60 years. The 
lack of homogeneity in the reported data about the 
prevalence of MCI may be due to the differences in 
the test used for the detection of MCI, the varieties in 
the application of MCI diagnostic criteria, the 
demographic characteristics of the shared 
populations, the education level and the age range of 
the participants. 
The current study aimed to identify the 
demographic factors associated with cognitive 
function. The results showed that the prevalence of 
MCI was insignificantly higher at the age of 50-55 
years (P > 0.05), which contradicts previous results 
that showed a trend that the prevalence of MCI 
increased with increasing age [28].
 
This could be 
attributed to the fact that all the participants at higher 
age group had post-graduate education. We found 
that all 32 participants with post-graduate education 
had normal cognition. A previous study found that 
education was an effective preventive factor against 
MCI [29].
 
People with a lower level of education were 
more likely to develop MCI. Possible reasons may be: 
high level of education can make changes to the brain 
metabolism and the degree of biological neural 
synaptic connections so that the brain can tolerate 
functional or structural defects in the brain cells to a 
certain extent. Instead, for people with lower levels of 
education, there is a lack of knowledge to stimulate 
the brain, causing massive loss of neurons [30].
 
Another possible reason is the health; poverty and 
socio-economic status which are associated with 
lower education level [31]. 
Our findings revealed no difference as 
regards the prevalence of MCI among males (8.2%) 
compared to females (7.1%), P > 0.05. Similarly, 
Ferreira et al., [32]
 
reported that there were no sex 
differences as regards the rates of cognitive decline in 
the normal ageing process. On the contrary, 
Caracciolo et al., and Roberts et al., [33], [34]
 
found 
that the incidence of MCI was higher among men. The 
pathological mechanisms that could explain these 
patterns precisely are still concealed. However, the 
pathophysiological changes regulated by endocrinal 
transition states, such as the menopause may have a 
role [35]. 
Midlife obesity has consistently been 
considered as a risk factor for the decline of cognitive 
function [36].
 
Our findings revealed that the mean BMI 
was significantly higher among participants having 
MCI (35.5 ± 7.2) compared to those with normal 
cognition (30.8 ± 5.6), P < 0.01. Similarly, Salama et 
al., [27]
 
found that the prevalence of objective MCI 
was 42.6% among obese compared to 11.6% among 
non-obese. In a population-based study, participants 
who were obese had twice the risk of developing 
dementia (OR = 2.10) [36]. 
In the current study, the prevalence of MCI 
was significantly higher among smokers (16.1%) 
compared to non- smokers (5.8%), with OR 3.1 (0.96-
10.1). It was reported that cognitive dysfunction 
accounted for 75.6% among smokers, compared to 
only 52.5% among nonsmokers, suggesting that 
smoking is a risk factor for MCI. During smoking, 
carbon monoxide fumes, as well as tobacco nicotine, 
tar and other harmful substances are produced, which 
will cause vascular endothelial damage, myosin 
contraction, and increase vascular permeability to 
accelerate atherosclerosis. Smoking may impair 
cognitive function through its effect on the arterial wall, 
leading to thickening of arterial plaque, increasing 
plasma viscosity and fibrinogen levels, platelet 
aggregation, hypertension and increases the risk of 
stroke [30]. 
A history of traumatic brain injury may 
possess a higher risk of having neurodegenerative 
diseases such as MCI and dementia across the life 
span [37].
 
The relation between traumatic brain injury 
and the risk of dementia later in life has been 
repeatedly established [38], [39].
 
In the present study, 
the prevalence of MCI was not significantly different 
between subjects having previous head trauma and 
those without, P > 0.05. May be that the reported 
head trauma in the current study was mild and did not 
lead to brain injury. 
The present study assessed the effects of 
lifestyle habits and leisure activities on cognition. 
Participants with normal cognition were found to be 
monthly consuming a significantly higher level of 
vegetables, fruits and unroasted nut compared to MCI 
subjects, P < 0.05. It was found that eating a healthy 
balanced diet that contains fruits, vegetables, 
unrefined cereal grains and nuts, and avoiding fatty 
and high-calorie foods was directly related to normal 
cognition [40].
 
The Mediterranean diet was reported 
as a preventive factor against MCI and AD diseases 
[41]. A study done by Pasinetti and Eberstein [42]
 
found that polyunsaturated fatty acids, vegetables, 
and a high Mediterranean-diet score may improve 
cognitive activity. A balanced diet with fewer calories 
and low glucose may enhance carbohydrate 
metabolism and decrease obesity which will 
effectively reduce the risk of hyperglycemia and thus 
avoiding Alzheimer’s disease [43].
 
On the other hand, 
persons with Alzheimer’s disease reported high 
consumption of animal protein and sugar in 
comparison to healthy controls who consumed more 
vegetables, fruits and whole grains [44].
 
Prevention of 
the deterioration of cognitive functions and dementia 
is directly related to the intake of certain nutrients or 
dietary antioxidant supplements [45]. 
Increased level of engagement in physical 
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activities is an important factor that increases the 
cognitive reserves [29].
 
We found that the prevalence 
of MCI was significantly higher among inactive 
subjects (15%) compared to those who were 
practising physical exercise (4.1%), OR 4.2 (1.2-14.5). 
In a population-based study, and frequency of 
moderate-intensity exercise had a protective effect on 
MCI. Those findings were consonant in both sexes. 
Light and intense physical activities were not 
significantly associated with MCI [46]. 
There is growing evidence demonstrating that 
participation in different forms of leisure activities, 
either mental or social activities have a good effect on 
well-being, especially for conserving functional 
capacity during the ageing procedure and decreasing 
the risk of chronic diseases [47], [49].
 
In the present 
study, the mean time in hours/week spent in 
intellectual games, reading and social activities were 
significantly higher among participants with normal 
cognition compared to subjects with MCI, P < 0.01. 
Several studies agreed with the results of the current 
study and reported that computer activities, reading, 
dancing, playing games and musical instruments 
decrease the risk of MCI and dementia [50], [51], [52]. 
In the present study, there was no significant 
association between lipid profiles and FBS and the 
risk of MCI. Similarly, other studies reported that lower 
concentration of HDL was associated with lower 
cognitive function, suggesting a positive correlation 
between HDL and cognitive function [53], [54].
  
A study done by Mielke and his colleagues 
[55]
 
concluded that high cholesterol level at old age 
was associated with reduced risk of dementia. 
However, Yaffe et al., [56]
 
and He et al., [57]
 
found 
that cholesterol and triglyceride levels were 
significantly higher among individuals with MCI 
subjects compared to those with normal cognition. 
Increase in serum cholesterol might cause damage to 
the brain capillary endothelial cells and accelerate 
atherosclerosis, then reduce cerebral blood flow, 
leading to the impaired cognitive function [30]. 
Evolution of reliable and non-invasive 
procedures for detecting subjects with MCI is 
important. It could help in increasing the efficiency of 
existing and new therapies and observing the 
advancement of disease [58]
 
(Michael-Titus et al., 
2010). Sheinerman et al., in 2012 [59]
 
performed a 
pilot study for selecting promising miRNA biomarkers 
for detecting MCI. Two sets of biomarkers (the miR-
132 and miR-134 families paired with miR-491-5p and 
miR-370) showed high specificity and sensitivity in 
recognising MCI subjects. Moreover, Sheinerman et 
al., [60]
 
validated these two sets of 50 MCI patients 
and 50 controls. They reported that these two sets 
could distinguish MCI from normal controls with 84%-
94% sensitivity and 96%-98% specificity for miRNA-
132 family and 74%-88% sensitivity and 80%-92% 
specificity for miRNA-134 family. 
In the present work, we aimed at validating 
these two miRNA-132 and miR-134 families (paired 
with miR-491-5p and miR-370 respectively), as 
biomarkers for the detection of MCI. Surprisingly, 
these two sets revealed much lower sensitivity and 
specificity in detecting MCI. Family miRNA 132 
expressions differentiated individuals with MCI from 
those with normal cognition with 60%-70% sensitivity 
and 57.9%-68.6% specificity.  
For family miRNA, 134 expressions 
differentiated individuals with MCI from those with 
normal cognition with 40%-60% sensitivity and 65.2%-
83.3% specificity. However, only miRNA 132 
expression was significantly upregulated among 
individuals with MCI compared to those with normal 
cognition, with a significant AUC 0.69 (0.52-0.86), 
70% sensitivity, 68.6 specificities and accuracy 
69.3%.  
These results preliminarily indicated that 
miRNA-132 might be a potential biomarker for the 
diagnosis of MCI. A significantly upregulated 
expression of miRNA-132 was reported among 
patients with MCI (n = 66) in comparison to their age-
matched controls (n = 76) [61].
 
Moreover, Weinberg et 
al., [62]
 
assessed miRNA 132 in the frontal and 
inferior temporal cortex of postmortem brains of 
patients with MCI and normal individuals and found 
that miR 132 was significantly down-regulated in MCI. 
Many studies have reported the value of miRNA-132 
in managing dendritic morphology. MiR-132 is 
important for the functional integrity of adult neurons 
reduces synaptic transmission between neurons in the 
hippocampus and has a key role in controlling 
cognitive functions [63], [64], [65]. While, Dhahbi et 
al., [66] reported that ageing is associated with an 
increase in the levels of miR-134 and miR-874 
expression. 
The accuracy of miRNAs as diagnostic and/or 
prognostic biomarker of MCI is inconsistent among 
several studies which could be attributed to different 
factors including different sample collection 
techniques regarding temperature, freezing and 
centrifugation of the drawn blood sample, different 
sample size, difference in selection of the participants 
as some studies matched cases and controls 
depending on gender and age while others relied on 
gender and ethnicity, different analytical methods and 
publication bias (where negative studies may be 
difficult to be found when searching on usual 
databases) which may overestimate the connection 
between miRNAs and MCI [67], [68]. 
In conclusion, the risk of MCI could be 
reduced by targeting modifiable risk factors. MiRNAs 
showed low sensitivity and specificity. However, 
miRNA 132 expression might be used as a minimally 
invasive test for detection of MCI. 
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